Nuvalent, Inc.
NASDAQ:NUVL
Overview | Financials
Company Name | Nuvalent, Inc. |
Symbol | NUVL |
Currency | USD |
Price | 84.22 |
Market Cap | 5,984,046,182 |
Dividend Yield | 0% |
52-week-range | 61.795 - 113.51 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. James R. Porter Ph.D. |
Website | https://www.nuvalent.com |
An error occurred while fetching data.
About Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD